The global Chronic Aspergillosis Treatment Market is estimated to be valued at US$ 3.21 Bn in 2023 and is expected to exhibit a CAGR of 5.0% over the forecast period 2024 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market Overview:
Chronic aspergillosis treatment products are used to treat chronic pulmonary aspergillosis infections. These include antifungal drugs such as voriconazole and itraconazole which inhibit fungal growth. Chronic aspergillosis often develops in people with pre-existing lung diseases and requires long term management.
Market key trends:
One of the key trends in the chronic aspergillosis treatment market is the rising number of clinical trials for novel products. For instance, Pulmocide Ltd. is developing inhaled antifungalvoriconazole (POB-101) for the treatment of severe asthmatic patients with allergic bronchopulmonary aspergillosis (ABPA). Inhaled drugs ensure direct delivery of antifungals to the site of infection in the lungs and are more effective compared to oral drugs. They also help reduce systemic side effects. This novel drug delivery approach is expected to boost the growth of the chronic aspergillosis treatment market during the forecast period.
Segment Analysis
The chronic aspergillosis treatment market is segmented into type and drugs. Based on type, the market is segmented into allergic bronchopulmonary aspergillosis (ABPA), chronic pulmonary aspergillosis (CPA), chronic sino-pulmonary aspergillosis, and chronic cutaneous aspergillosis. The ABPA segment dominates the market as it is the most common form of chronic aspergillosis. Symptoms like shortness of breath, coughing, fever etc. are caused due to ABPA, making it a dominating segment.
Key Takeaways
The global chronic aspergillosis treatment market is expected to witness high growth, exhibiting CAGR of 5.0% over the forecast period, due to increasing prevalence of chronic aspergillosis diseases across the world.
Regional analysis
North America is expected to dominate the global chronic aspergillosis treatment market owing to increasing approval for novel drugs and developed healthcare infrastructure in the region. Europe is expected to be the second largest market due to presence of key players focusing on R&D activities for developing advanced therapies.
Key players
Key players operating in the chronic aspergillosis treatment market are Astellas Pharma Inc., Abbott Laboratories, Pfizer Inc., Pulmocide Ltd., Johnson & Johnson, Mylan N.V., Glenmark Pharmaceuticals, Merck & Co., Inc., Mayne Pharma Group Limited, GlaxoSmithKline plc., PULMATRiX, Inc., F2G Ltd, Teva Pharmaceutical Industries Ltd., and Novartis International AG.
No comments:
Post a Comment